Combining hormone therapy with chemotherapy and HER2-targeted treatment before surgery for HER2+ breast cancer
Official title: Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer
Run by Legacy Health System · NCT07506876 · Data updated 2026-11-12
This trial will try giving hormone (endocrine) therapy at the same time as chemotherapy and HER2-targeted drugs for adults with HR+, HER2+ breast cancer to see if tumors respond better before surgery.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Legacy Health System Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 4 sites (Gresham, Oregon and 3 other locations) |
| Status | Recruiting |
| Started | April 27, 2026 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | May 1, 2026 |
| Trial ID | NCT07506876 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with newly diagnosed, previously untreated hormone receptor–positive, HER2+ invasive breast cancer, clinical stage IIA–IIIC, with luminal A/B or HER2-enriched subtype by MammaPrint/BluePrint, who plan to receive at least four cycles of TCHP are ideal candidates.
✕Probably not a fit
Patients with stage IV disease, recurrent breast cancer, recent non-breast cancers within two years, those under 18, pregnant, or whose tumor subtype does not meet the MammaPrint/BluePrint criteria are unlikely to receive benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2 interventional trial gives concurrent endocrine therapy alongside standard neoadjuvant chemotherapy and HER2-directed therapy (TCHP) for adults with newly diagnosed HR+, HER2+ invasive breast cancer. Eligible patients are clinical stage IIA–IIIC and must have luminal A, luminal B, or HER2-enriched subtype by MammaPrint/BluePrint on the initial biopsy. Endocrine therapy may be started up to 28 days before enrollment and must be in place before the second cycle of chemotherapy, with a planned minimum of four cycles of TCHP. The main outcome is tumor response at the time of surgery (pathologic response) to determine if concurrent endocrine therapy increases treatment effect.
Why it matters
Potential benefit: If successful, this approach could increase tumor shrinkage before surgery, possibly allowing less extensive surgery and improving long-term outcomes.
How similar studies have gone: The idea of giving endocrine therapy concurrently with chemo and HER2-targeted agents is relatively novel—most prior neoadjuvant approaches give endocrine therapy after chemo/HER2 therapy and there are limited data showing clear benefit for concurrent use.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adults over 18 years of age with newly diagnosed, previously untreated, HR+, HER2+ breast cancer (positive per local guidelines) 1. Endocrine therapy for the current breast cancer may be started within 28 days prior to trial enrollment and must be initiated prior to C2 of chemotherapy/HER2 directed therapy 2. Choice of endocrine therapy will be determined by the treating and/or enrolling physician 2. Anatomic Stage IIA - IIIC breast cancer planning a minimum of 4 cycles of TCHP 3. Patients must be Luminal A, Luminal B or HER2 enriched subtype on MammaPrint/BluePrint performed on initial biopsy Exclusion Criteria: 1. Children under 18 years of age, pregnant women, prisoners, and decisionally impaired adults. 2. Patients with non-breast cancer within prior 2 years 3. Patients with breast cancer within prior 5 years 4. Patients with recurrent breast cancer 5. Patients with stage IV breast cancer
Where it's running
-
Legacy Mount Hood Medical Center
Gresham, Oregon, United States Recruiting -
Legacy Good Samaritan Medical Center
Portland, Oregon, United States Recruiting -
Legacy Meridian Park Medical Center
Tualatin, Oregon, United States Recruiting -
Legacy Salmon Creek Medical Center
Vancouver, Washington, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Magtrace bracketing to guide lumpectomy and sentinel node biopsy
This study tests whether Magtrace bracketing can help accurately locate the tumor and sentinel lymph node during breast-conserving surgery.
-
Brain MRI surveillance for HER2-positive metastatic breast cancer
This study tests whether adding regular brain MRIs helps detect hidden brain involvement earlier in people with HER2-positive metastatic breast cancer.
-
Using a pertuzumab biosimilar for HER2-positive breast cancer before surgery and as first-line treatment for metastatic disease
This project will look at how a pertuzumab biosimilar is used and how patients with HER2-positive breast cancer do when given it before surgery or as first-line treatment for metastatic disease.
-
Oncoliq blood test for early detection of breast cancer
This project will test whether a blood-based miRNA panel (the Oncoliq Test) can detect early breast cancer in adults 40–70 by comparing newly diagnosed, untreated patients with cancer-free controls.
-
A166 for HER2-positive advanced or metastatic breast cancer
This trial will test whether A166 helps adults with HER2-positive unresectable or metastatic breast cancer who previously received a topoisomerase inhibitor–based HER2 antibody-drug conjugate.
-
SIRA-1000 radiofrequency ablation of lumpectomy margins
This study tests whether using the SIRA-1000 radiofrequency device at the edge of the lumpectomy cavity during breast-conserving surgery can destroy remaining cancer cells in women 50 and older with ER/PR+ invasive ductal breast cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.